ライフサイエンスコーパス: RF ablation

1 RF ablation in elderly patients with nonresected breast

2 RF ablation induces a strong time-dependent immunologic

3 RF ablation is a common yet benign cause of transient PV

4 RF ablation is a cost-effective treatment option for pat

5 RF ablation may be an effective, minimally invasive meth

6 RF ablation may be clinically beneficial and should be c

7 RF ablation of 21 malignant lesions was performed in 20

8 RF ablation of lung tumors resulted in the greatest coag

9 RF ablation of normal liver can stimulate distant subcut

10 RF ablation of RCC can be successful in exophytic RCC tu

11 RF ablation reduced the i.v. Doxil dose needed to achiev

12 RF ablation resulted in resolution of targeted FDG avidi

13 RF ablation to the maximum system current output (2000 m

14 RF ablation was performed by two radiologists using an i

15 RF ablation was performed with a 1-cm tip and 5 minutes

16 RF ablation was performed with a single-tip electrode by

17 RF ablation was preferred over NSS for small RCC treatme

18 RF ablation, ITDC, and combined groups demonstrated simi

19 RF ablations (n = 258) were performed in ex vivo bovine

20 First, 10 RF ablations were performed at 20-60 W for 12 minutes.

21 Sixty ablations (30 MW and 30 RF ablations) were performed ex vivo in 15 bovine livers

22 Then, 31 RF ablations were performed with optimal settings in viv

23 RF ablation-paclitaxel (17.6 days +/- 2.5), RF ablation-doxorubicin (30.3 days +/- 4.9, P < .002), o

24 omal doxorubicin (10 mg per animal) (n = 6), RF ablation alone (n = 6), and liposomal doxorubicin alo

25 , mice were randomized into control (n = 7), RF ablation, ITDC (n = 9), and RF ablation + ITDC (n = 9

26 e randomized into four treatment groups: (a) RF ablation (70 degrees C for 5 minutes) alone, (b) RF a

27 grafts (six per group) were treated with (a) RF ablation (70 degrees C for 5 minutes), (b) PEGylated

28 correlation with myofibroblast accumulation, RF ablation induced hepatocyte proliferation in both the

29 Adding RF ablation to systemic chemotherapy achieved local cont

30 After RF ablation of normal liver, distant R3230 tumors were s

31 After RF ablation, 15 (42%) patients developed low-grade fever

32 After RF ablation, coagulation diameter in the subcutaneous tu

33 After RF ablation, CT images, aldosterone-to-renin ratio (ARR)

34 After RF ablation, the ablated region had almost zero activity

35 was conducted on days 1, 3, 5, and 10 after RF ablation or biopsy.

36 , and blood pressure levels before and after RF ablation was performed by using the Wilcoxon signed-r

37 patient mood were measured before and after RF ablation.

38 yte proliferation was also seen 7 days after RF ablation in the distant liver (ablated lobe: P = .003

39 tions of tissue adherent to electrodes after RF ablation of liver malignancies were performed, with a

40 By 4 hours after RF ablation alone, a 0.48-mm +/- 0.13 (standard deviatio

41 blation zone was performed immediately after RF ablation (mean number of biopsy samples per ablation

42 ts, local delivery of 5-FU immediately after RF ablation provided a significant (P < .05) reduction i

43 ne responses when injected immediately after RF ablation.

44 in mice treated with a c-met inhibitor after RF ablation by using the Mann-Whitney U test.

45 ined immediately, 2 weeks, and 1 month after RF ablation.

46 LTP within 12 months after RF ablation was noted in 3% (95% CI: 0, 9) of necrotic C

47 tive probabilities of local recurrence after RF ablation and NSS, the short-term costs of both, and q

48 peration and to inhibit HCC recurrence after RF ablation in a mouse model of spontaneously forming HC

49 Recurrence after RF ablation was local in 13 (38%), intrapulmonary in six

50 ught to contribute to local recurrence after RF ablation.

51 and quantification of LA wall scarring after RF ablation in patients with AF.

52 nimum of 3 years to more than 10 years after RF ablation (n = 99, 67, 49, and 25 for 3, 5, 7, and 10

53 Compared with RF ablation alone, RF ablation combined with adjuvant PHA-665752 or semaxan

54 Results Although RF ablation was associated with a well-defined periablat

55 itaxel-RF ablation (6.76 mug/g +/- 0.35) and RF ablation-paclitaxel (9.28 mug/g +/- 0.87) increased o

56 trol (n = 7), RF ablation, ITDC (n = 9), and RF ablation + ITDC (n = 9) groups and monitored for tumo

57 One patient underwent biopsy and RF ablation of an FDG-avid hepatic focus.

58 revealed that increased maximum current and RF ablation durations of up to 20 minutes were associate

59 treatment by using 5-FU polymer implants and RF ablation shows uniform sustained release of 5-FU for

60 MW and RF ablation zones are similar in pathologic appearance a

61 MW and RF ablation zones were indistinguishable at CT or pathol

62 ation and post-NSS local recurrence, NSS and RF ablation short-term costs, and post-NSS quality of li

63 gnificantly greater with 20-Gy radiation and RF ablation combined: 94 days +/- 34 (P < .001 compared

64 Coaxial biopsy needle introducer tips and RF ablation electrode guider needle tips containing elec

65 MW ablation compared with 26.2% +/- 27.9 at RF ablation (P < .05).

66 tion (70 degrees C for 5 minutes) alone, (b) RF ablation followed by radiation therapy with a total d

67 Tumors received (a) no treatment, (b) RF ablation, (c) paclitaxel, (d) RF ablation followed by

68 (15)O-water PET images were acquired before RF ablation and after the first RF and second RF ablatio

69 atients had symptoms of their disease before RF ablation.

70 NAC) administered 24 hours and 1 hour before RF ablation.

71 ablation-paclitaxel), (e) paclitaxel before RF ablation (paclitaxel-RF ablation), (f) RF ablation fo

72 taxel-doxorubicin), or (h) paclitaxel before RF ablation, followed by doxorubicin (paclitaxel-RF abla

73 after a mean interval of 7.5 months between RF ablation and transplantation.

74 Laboratory test results were similar between RF ablation-only animals and MW ablation-only animals, w

75 or shape of ablations created by the bipolar RF ablation device tested.

76 - 0.8, respectively; P < .05 for IRE vs both RF ablation and sham operation).

77 Liver regeneration induced by RF ablation facilitates c-met/hepatocyte growth factor a

78 Conclusion Liver regeneration induced by RF ablation facilitates c-met/hepatocyte growth factor a

79 oninvasive identification of scar induced by RF ablation following isolation therapy of the PV.

80 bined liposomal doxorubicin and 70 degrees C RF ablation (P <.01).

81 bined liposomal doxorubicin and 90 degrees C RF ablation survived longer than did animals that receiv

82 (b) liposomal doxorubicin (1 mg) alone, (c) RF ablation followed by liposomal doxorubicin, and (d) n

83 one (1.6 cm +/- 0.7) surrounding the central RF ablation-induced white coagulation zone.

84 Combined RF ablation and 20-Gy radiation resulted in complete loc

85 Combined RF ablation and external-beam radiation therapy increase

86 Combined RF ablation and liposomal doxorubicin retards tumor grow

87 ablation alone (13 procedures) and combined RF ablation and ethanol injection (21 procedures).

88 Combining RF ablation with liposomal doxorubicin increases cell in

89 to one of two treatment groups: conventional RF ablation (90 degrees C +/- 2, 5 minutes) followed by

90 to three treatment groups: internally cooled RF ablation (12 minutes, 2000-mA pulsed technique) follo

91 tion using irrigated radiofrequency current (RF) ablation and 3-dimensional mapping.

92 atment, (b) RF ablation, (c) paclitaxel, (d) RF ablation followed by paclitaxel (RF ablation-paclitax

93 ge quality-adjusted life expectancy than did RF ablation (2.5 days) but was more expensive.

94 tal venous branch points (P < .001) than did RF ablation alone.

95 56 years) were treated with single or double RF ablation sessions prior to liver transplantation.

96 n), (f) RF ablation followed by doxorubicin (RF ablation-doxorubicin), (g) paclitaxel followed by dox

97 uction of renal blood flow before and during RF ablation resulted in larger thermal lesions with pote

98 e method of reducing tumor blood flow during RF ablation, enabling larger zones of tumor destruction

99 contrast-enhanced US images increased during RF ablation and reached a maximum within 2 days after ab

100 One small pneumothorax was noted during RF ablation but stabilized without intervention.

101 current, and impedance were recorded during RF ablation.

102 her 19 tumors were randomized to receive (e) RF ablation (70 degrees C for 5 minutes) followed by 5-G

103 mas in Fischer rats were treated with either RF ablation (n = 43), 1 mg of intravenously injected lip

104 ems used as controls, the multiple-electrode RF ablation system enabled the creation of significantly

105 re RF ablation (paclitaxel-RF ablation), (f) RF ablation followed by doxorubicin (RF ablation-doxorub

106 Fifteen RF ablation lesions were created in nine kidneys by usin

107 nificantly inhibited by NAC 1 hour following RF ablation, resulting in decreased cleaved caspase-3 po

108 For RF ablation lesions, the mean LAD, SAD, and volume demon

109 an) for combined therapy and 0.9 +/- 0.2 for RF ablation alone (P < .004).

110 ation with the single electrode and that for RF ablation with the electrode cluster.

111 oablation in this model was between that for RF ablation with the single electrode and that for RF ab

112 sensitive to changes in size thresholds for RF ablation, the number of metastases present, and surge

113 Group D underwent either four MW or four RF ablations.

114 Contrast-enhanced US can guide RF ablation of the entire prostate.

115 Computed tomography (CT)-guided RF ablation and contrast material-enhanced 1-month follo

116 Percutaneous computed tomography (CT)-guided RF ablation of lung nodules was performed 48 hours after

117 Preliminary data suggest that CT-guided RF ablation is an effective technique for local control

118 Conclusion CT-guided RF ablation is an effective treatment for APA, with high

119 nderwent percutaneous fluoroscopic CT-guided RF ablation.

120 ithin the past 6 months, underwent US-guided RF ablation while under local anesthesia and sedation.

121 The livers of 28 rats underwent US-guided RF ablation.

122 Hepatic RF ablation induces not only a local periablational infl

123 Hepatic RF ablation predominantly increased periablational and s

124 e tumor cells on the electrode after hepatic RF ablation is an independent predictor of LTP.

125 Finally, hepatic RF ablation was performed in rats with c-Met-negative R3

126 First, the effect of hepatic RF ablation on distant subcutaneous in situ R3230 and MA

127 Second, hepatic RF ablation was performed for hepatocyte growth factor (

128 Third, hepatic RF ablation was combined with either a c-Met inhibitor (

129 For c-Met-negative tumors, hepatic RF ablation did not increase distant tumor growth, proli

130 gher alkaline phosphatase levels at day 2 in RF ablation-only animals (P < .02).

131 Rechallenged mice in RF ablation, ITDC, and combination groups demonstrated s

132 sis and HSP production effectively increases RF ablation-induced tumor coagulation and end-point surv

133 which suggests that more aggressive initial RF ablation and adjuvant radiation may offer improvement

134 majority of inducible VTs using an irrigated RF ablation catheter.

135 rates a systemic immune response after local RF ablation in a mouse model.

136 Lung RF ablation appears to be safe and linked with promising

137 tients with primary NSCLC who underwent lung RF ablation from January 1998 to January 2008 were revie

138 Conclusion Unlike monopolar RF ablation, change in portal vein flow rates does not h

139 onale for combined therapeutic approaches of RF ablation followed by a systemic application of immuno

140 endogenous tumor vaccine; in this context of RF ablation-triggered immune system stimulation, the rep

141 These 16 mice received a standard dose of RF ablation.

142 er regeneration in the tumorigenic effect of RF ablation.

143 luating the (societal) cost-effectiveness of RF ablation and hepatic resection in patients with CRC l

144 accurate tool for monitoring the effects of RF ablation and quantifying the size of thermal damage a

145 ave potential to overcome the limitations of RF ablation and warrant further clinical investigation.

146 nt with Pluronic P85 improved the outcome of RF ablation by decreasing the tumor volume and residual

147 To assess the reproducibility of RF ablation, RF lesions were created repeatedly at the i

148 The size of RF ablation lesions is highly variable, with a significa

149 .1 mm +/- 1.3, P < .01) compared with use of RF ablation alone (liver, 13.4 mm +/- 1.5; kidney, 7.9 m

150 Use of RF ablation combined with liposomal doxorubicin facilita

151 Because of this efficacy, the use of RF ablation in children has become standard of care even

152 The use of RF ablation with liposomal doxorubicin and (186)Re-lipos

153 an estimated NSS cost reduction of $7500 or RF ablation cost increase of $6229.

154 ared with that for paclitaxel-RF ablation or RF ablation-paclitaxel (17.6 days +/- 2.5), RF ablation-

155 xorubicin (5 mg per rabbit, 1 mg per rat) or RF ablation alone (n = 5, each).

156 ffective and may represent an advantage over RF ablation alone.

157 RF ablation increased tumor coagulation over RF ablation or paclitaxel (mean, 14.0 mm +/- 0.9 [standa

158 xel, (d) RF ablation followed by paclitaxel (RF ablation-paclitaxel), (e) paclitaxel before RF ablati

159 Paclitaxel-RF ablation increased tumor coagulation over RF ablation

160 Paclitaxel-RF ablation-doxorubicin had similar tumor coagulation (P

161 e) paclitaxel before RF ablation (paclitaxel-RF ablation), (f) RF ablation followed by doxorubicin (R

162 blation, followed by doxorubicin (paclitaxel-RF ablation-doxorubicin).

163 moral paclitaxel accumulation for paclitaxel-RF ablation (6.76 mug/g +/- 0.35) and RF ablation-paclit

164 s greater, compared with that for paclitaxel-RF ablation or RF ablation-paclitaxel (17.6 days +/- 2.5

165 Mean end-point survival for paclitaxel-RF ablation-doxorubicin (56.8 days +/- 25.3) was greater

166 gulation (P < .05), compared with paclitaxel-RF ablation, at 24 and 96 hours.

167 ccess when selecting patients for palliative RF ablation of painful solitary osseous metastases.

168 Percutaneous RF ablation is an alternative to surgery for treatment o

169 e CT densitometry and CT-guided percutaneous RF ablation of 19 lung tumors (six [32%] tumors were ade

170 ted tomographically (CT) guided percutaneous RF ablation was evaluated in 36 patients (19 men; mean a

171 nderwent ultrasonography-guided percutaneous RF ablation with internally-cooled electrodes in associa

172 computed tomography (CT)-guided percutaneous RF ablation.

173 e preliminary results show that percutaneous RF ablation is a safe and technically feasible managemen

174 cted of 215 patients undergoing percutaneous RF ablation of hepatic tumors.

175 computed tomography (CT)-guided percutaneous RF ablations of liver tumors in 26 patients (13 men, 13

176 nd an RF power source to monitor and perform RF ablation in bovine muscle and human artery samples in

177 le trend ((186)Re-liposomal doxorubicin plus RF ablation > (186)Re-liposomal doxorubicin > liposomal

178 mal doxorubicin > liposomal doxorubicin plus RF ablation > liposomal doxorubicin) of improved tumor g

179 ated with (186)Re-liposomal doxorubicin plus RF ablation (0.54 cm(3) +/- 0.38; P < .001 vs all groups

180 RF ablation, (g) liposomal doxorubicin plus RF ablation, (h) (186)Re-PEGylated liposomes plus RF abl

181 n, or (i) (186)Re-liposomal doxorubicin plus RF ablation.

182 n (555 MBq/kg), (f) PEGylated liposomes plus RF ablation, (g) liposomal doxorubicin plus RF ablation,

183 lation, (h) (186)Re-PEGylated liposomes plus RF ablation, or (i) (186)Re-liposomal doxorubicin plus R

184 Post-RF ablation patients with symptoms experienced significa

185 Complete post-RF ablation syndrome occurs in approximately one-third o

186 Twelve (33%) patients had complete post-RF ablation syndrome: fever and flulike symptoms (P = .0

187 endent on the relative probabilities of post-RF ablation and post-NSS local recurrence, NSS and RF ab

188 emained so if the annual probability of post-RF ablation local recurrence was up to 48% higher relati

189 es can be achieved with optimized high-power RF ablation.

190 Pre-RF ablation images demonstrate that (15)O-water accumula

191 sition on 3D MRI allows accurate and precise RF ablation guided by the true anatomy.

192 Radiofrequency (RF) ablation has shown superior anticancer effects and g

193 Radiofrequency (RF) ablation may have the potential to turn a patient's

194 Radiofrequency (RF) ablation of the myocardium causes discrete sites of

195 Radiofrequency (RF) ablation treatment for tachyarrhythmias has been ava

196 umor progression (LTP) after radiofrequency (RF) ablation of colorectal cancer liver metastasis (CLM)

197 noma (HCC) development after radiofrequency (RF) ablation, partial surgical hepatectomy, and a sham o

198 lations created by a bipolar radiofrequency (RF) ablation device.

199 luate whether scar caused by radiofrequency (RF) ablation of the left atrium (LA) in patients with at

200 Combining radiofrequency (RF) ablation with i.v. liposomal doxorubicin (Doxil) inc

201 open irrigation facilitates radiofrequency (RF) ablation.

202 ry when percutaneous hepatic radiofrequency (RF) ablation is performed adjacent to the diaphragm.

203 cutaneous minimally invasive radiofrequency (RF) ablation has not been described for lymphoma.

204 us rhythm using an irrigated radiofrequency (RF) ablation catheter.

205 emic "off-target" effects of radiofrequency (RF) ablation and irreversible electroporation (IRE), Bul

206 , and recurrence outcomes of radiofrequency (RF) ablation in treating primary aldosteronism due to al

207 ophysical characteristics of radiofrequency (RF) ablation lesions generated by either standard or coo

208 the intratumoral coverage of radiofrequency (RF) ablation therapy.

209 ation improved the safety of radiofrequency (RF) ablation, but the thermal feedback for energy titrat

210 tes and clinical outcomes of radiofrequency (RF) ablation, Yan et al validated the use of a tumor-pen

211 Saline-linked surface radiofrequency (RF) ablation is a new technique for applying RF energy t

212 thermal ablation techniques-radiofrequency (RF) ablation, microwave ablation, laser ablation, and cr

213 ere able to demonstrate that radiofrequency (RF) ablation-induced liver regeneration promotes "off-ta

214 t types of ablation: thermal radiofrequency (RF) ablation and electroporative ablation with irreversi

215 ) showed that, compared with radiofrequency (RF) ablation, larger and more circular zones of thermal

216 aphic (CT)-guided lung tumor radiofrequency (RF) ablations performed at a tertiary care cancer hospit

217 The third patient received RF ablation for prevention of airway obstruction from pr

218 The second patient received RF ablation for successful palliation of progressive fol

219 The first patient received RF ablation for the curative treatment of a solitary res

220 ence in the technical success rates of renal RF ablation.

221 A search of the renal RF ablation database (235 patients) identified 23 consec

222 in three (8%) patients who required a second RF ablation.

223 The second RF ablation in this new region of the tumor resulted in

224 F ablation and after the first RF and second RF ablations using a small-animal PET scanner.

225 al (progression) as a function of time since RF ablation.

226 in 33 (92%) patients who underwent a single RF ablation session.

227 Standard RF ablation lesions (n=33) using a 4-mm top catheter (go

228 However, the efficacy of standard RF ablation on the epicardial surface of the heart is hi

229 rdial lesions more effectively than standard RF ablation and appears to be of particular benefit in a

230 A standardized RF ablation dose (70 degrees C for 5 minutes) was used t

231 bbits) 1, 6, or 24 hours before standardized RF ablation, which was performed by using a 1-cm active

232 imals were randomly assigned to standardized RF ablation, sham procedure, or no treatment.

233 scopy time and radiation dose for subsequent RF ablation procedures.

234 All patients underwent subsequent RF ablation.

235 Subtotal RF ablation treatment results in enhanced systemic antit

236 Animals treated with subtotal RF ablation showed significant increases in tumor-specif

237 rgin within the untreated tissue surrounding RF ablation-treated tumors.

238 sions appears to require less analgesia than RF ablation.

239 re effective (in terms of QALYs gained) than RF ablation and has an incremental cost-effectiveness ra

240 sociated with a higher serum IL-6 level than RF ablation.

241 There was no evidence in this study that RF ablation of larger tumor percentage or larger volume

242 The RF ablation lesions were placed in a linear fashion trav

243 The RF ablation was performed using an irrigated-tip ablatio

244 The mean CT fluoroscopy time for the RF ablation procedure was 28 seconds +/- 11.7 (standard

245 onfirmed significantly greater uptake in the RF ablation-treated tumors (P < .001).

246 ITDC injection mimics the RF ablation effect but does not increase immune response

247 Within this study, the RF ablation zones from twelve post-interventional CT acq

248 ems that were thought to be unrelated to the RF ablation and was rendered pain-free after subsequent

249 Therefore, RF ablation was considered preferred and remained so if

250 Cooled-tip RF ablation can generate epicardial lesions more effecti

251 A 4-mm cooled-tip RF ablation catheter (continuous 0.9% saline circulation

252 Lesions created with standard and cooled-tip RF ablation were 3.7+/-1.3 mm (25+/-16.8 W) and 6.7+/-1.

253 he kidney vessels may be a useful adjunct to RF ablation of kidney tumors.

254 to tongues with MR imaging guidance prior to RF ablation in the chronic group.

255 ess ratio of $1,152,529 per QALY relative to RF ablation, greatly exceeding $75,000 per QALY.

256 s facilitating the wound healing response to RF ablation.

257 Tumor RF ablation therapy was performed on head and neck squam

258 ly 6.7 mm +/- 0.7 for animals that underwent RF ablation alone (P < .01).

259 flammation-induced HCC model) that underwent RF ablation, 35% partial hepatectomy (ie, left lobectomy

260 procedure records of patients who underwent RF ablation and cryoablation of renal tumors from June 1

261 eoplasms (<3.2 cm in diameter) who underwent RF ablation during a 7-year period.

262 Thirty-four patients who underwent RF ablation of 42 RCC tumors during a 3.5-year period we

263 e, 69.3 years; range, 40-88 years) underwent RF ablation for 26 liver tumors and 17 renal tumors.

264 four women; mean age, 68.1 years) underwent RF ablation of 15 renal tumors.

265 Two treatment modalities were used: RF ablation alone (13 procedures) and combined RF ablati

266 Histologic evidence directly validates RF ablation as an effective treatment of small (<3 cm) H

267 strates noninferiority of CB ablation versus RF ablation for treating patients with paroxysmal atrial

268 By using a 200-W RF ablation system and custom-fabricated MR imaging-comp

269 lation was associated with more PVG than was RF ablation alone.

270 Primary end points were RF ablation efficacy at 1 year on the basis of DCE MR im

271 ) for the control group, 34 days +/- 31 with RF ablation alone, and 43 days +/- 16 with 20-Gy radiati

272 ignificantly greater than that achieved with RF ablation alone (0.6 cm +/- 0.1, P < .01).

273 OX)-loaded nanoparticles in combination with RF ablation in a hepatocellular carcinoma mouse model.

274 IV liposomal quercetin in combination with RF ablation reduces tumor growth rates and improves anim

275 iposomal doxorubicin to tumors combined with RF ablation can be depicted and quantified with noninvas

276 Compared with RF ablation alone, RF ablation combined with adjuvant PH

277 arger with microwave ablation, compared with RF ablation.

278 vival was 12 days for controls, 20 days with RF ablation or 5-Gy radiation alone, 30 days with RF abl

279 ith 20-Gy radiation alone, and 120 days with RF ablation plus 20-Gy radiation.

280 lation or 5-Gy radiation alone, 30 days with RF ablation plus 5-Gy radiation, 40 days with 20-Gy radi

281 l for rats that received 5-Gy radiation with RF ablation versus without was 46 days +/- 37 versus 24

282 mor eradication rate than that reported with RF ablation.

283 of 13 lesions were treated successfully with RF ablation after one session.

284 is diameter was not different from that with RF ablation at any time point (P > .05).

285 Combination therapy with RF ablation after SPACE to treat unresectable lung tumor

286 6) compared with that in tumors treated with RF ablation (2.3 cm +/- 0.1) or liposomal doxorubicin (0

287 velopment in MDR2 knockout mice treated with RF ablation (P = .001).

288 ared with one (9%) of 11 tumors treated with RF ablation alone and one (17%) of six treated with RF a

289 tion alone and one (17%) of six treated with RF ablation and 5-Gy radiation (P < .001).

290 her compared with those of mice treated with RF ablation at 1 month after therapy by using a two-tail

291 proved chondroblastoma who were treated with RF ablation at two academic centers from July 1995 to Ju

292 r-old patients with a small RCC treated with RF ablation or NSS.

293 t were 3 mm or larger than mice treated with RF ablation or sham operation (mean, 3.6 +/- 1.3 [standa

294 Sixty-eight malignant tumors treated with RF ablation were identified.

295 Liver slices from mice treated with RF ablation were stained for alpha-smooth muscle actin a

296 was observed in canine sarcomas treated with RF ablation-liposomal doxorubicin (3.7 cm +/- 0.6) compa

297 of these 32.8% (41 of 125) were treated with RF ablation.

298 conclude that superior tumor treatment with RF ablation is possible when combined with molecular-tar

299 ratumoral paclitaxel uptake with and without RF ablation were compared.

300 ) paclitaxel followed by doxorubicin without RF ablation (paclitaxel-doxorubicin), or (h) paclitaxel